May And Baker Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.50 M
as on 24-10-2024
- Company Age 18 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 10.00 Cr
as on 24-10-2024
- Revenue 6.20%
(FY 2023)
- Profit -222.77%
(FY 2023)
- Ebitda -173.46%
(FY 2023)
- Net Worth -16.00%
(FY 2023)
- Total Assets 26.91%
(FY 2023)
About May And Baker Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹10.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Manju Bist, Ritu Mirg, and Pooja Sharma serve as directors at the Company.
- CIN/LLPIN
U15400DL2006PLC145272
- Company No.
145272
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
23 Jan 2006
- Date of AGM
26 May 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does May And Baker Pharmaceuticals Limited offer?
May And Baker Pharmaceuticals Limited offers a wide range of products and services, including Healthcare Devices, Thermometers.
Who are the key members and board of directors at May And Baker Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manju Bist  | Director | 02-Mar-2009 | Current |
| Ritu Mirg | Director | 02-Mar-2009 | Current |
| Pooja Sharma | Director | 15-May-2015 | Current |
Financial Performance and Corporate Structure Insights of May And Baker Pharmaceuticals.
May And Baker Pharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.2% increase. The company also saw a substantial fall in profitability, with a 222.77% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of May And Baker Pharmaceuticals?
In 2023, May And Baker Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 22 Jun 2023 | ₹5.00 Cr | Satisfied |
Yes Bank Limited Creation Date: 19 May 2017 | ₹5.00 Cr | Satisfied |
How Many Employees Work at May And Baker Pharmaceuticals?
May And Baker Pharmaceuticals has a workforce of 8 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of May And Baker Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped May And Baker Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
